The Dynamic Immune Signature of Patients with Advanced Non-small Cell Lung Cancer in Prediction of Infection After Receiving Immunotherapy

Pulmonary infection has been an important concern in patients with non-small cell lung cancer. It is well-known that chemotherapy may increase the infection rate by suppressing the immune system. Whether the clinical outcome of pulmonary infection is association with immunotherapy is still unclear. Mass cytometry is a next-generation flow cytometry platform with multiparametric analyses. Previous studies of mass cytometry showed that exhausted T cell were implicated in disease progression and response to immunotherapy.